Licaminlimab clinical trials
How each study uses licaminlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Oculis (2) · Alcon Research (1) · Alcon, a Novartis Company (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test licaminlimab, phase 3 first.
- Dec 2026A Clinical Study Evaluating Licaminlimab for Dry Eye DiseasePhase 2/3 · Oculis
Studies
Open first, then newest update. How each study uses licaminlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study Evaluating Licaminlimab for Dry Eye DiseaseActive, not recruitingPhase 2/3OculisNCT07548632Written as licaminlimab
- Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye DiseaseCompletedPhase 2OculisNCT05896670Written as licaminlimab
- Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior UveitisCompletedPhase 2Alcon ResearchNCT02482129Written as LME636 60 mg/mL ophthalmic solution
- LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye DiseaseCompletedPhase 2Alcon, a Novartis CompanyNCT02365519Written as LME636 ophthalmic solution
Codes
What other systems call licaminlimab · ClinicalTrials.gg INT016291
- UNII (FDA) D5ZJ707VIRLICAMINLIMABOne source FDA
- NCI Thesaurus C179100LicaminlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D5ZJ707VIR | LICAMINLIMAB | One source FDA |
| NCI Thesaurus | C179100 | Licaminlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.